Home/Filings/4/0001209191-23-014910
4//SEC Filing

Warner Brent 4

Accession 0001209191-23-014910

CIK 0001661460other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 6:30 PM ET

Size

9.1 KB

Accession

0001209191-23-014910

Insider Transaction Report

Form 4
Period: 2023-03-01
Warner Brent
President, Gene Therapy
Transactions
  • Award

    Common Stock

    2023-03-01+92,772400,653 total
  • Tax Payment

    Common Stock

    2023-03-01$5.35/sh26,617$142,401374,036 total
  • Award

    Stock Option (Right to Buy)

    2023-03-01+125,283125,283 total
    Exercise: $5.35Exp: 2033-02-28Common Stock (125,283 underlying)
Footnotes (3)
  • [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
  • [F2]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022.
  • [F3]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother

Related Parties

1
  • filerCIK 0001910914

Filing Metadata

Form type
4
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 6:30 PM ET
Size
9.1 KB